Aletho News


Where’s Walensky? – A Rebound update

The Naked Emperor’s Newsletter | October 31, 2022

CDC Director, Rochelle Walensky first tested positive for Covid on 21 October. This was weeks after getting her fifth jab. This is the same Rochelle who assured us that the vaccinated don’t carry the virus and don’t get sick. My Post – A picture is worth a thousand words highlighted her journey to Covid infection.

Well the vaccinated clearly do carry the virus.

And they clearly do get sick. Although Walensky only had mild symptoms she took a course of the antiviral pill Paxlovid. Paxlovid, on rare occasions, causes a COVID rebound, i.e. you start testing positive again. This is so rare, Jill Biden rebounded, Joe Biden rebounded and Anthony Fauci rebounded. They just all must be really unlucky.

People were getting worried about Walesnky. She had gone quiet for longer than expected. 10 days had passed and she had only been seen on the odd video. Where had she gone?

You’ve guessed it, after taking Paxlovid, Walensky has also rebounded. After testing negative, mild symptoms returned on Sunday and she is isolating at home again.

Paxlovid seems to return symptoms quicker than the Speed of Science.

The question is, why are they all so keen to tell us that their safe and effective vaccines and drugs are no longer effective? They could easily disappear for a few weeks and nobody would be any the wiser that they had rebounded or even contracted mild Covid in the first place. There is clearly a nudging agenda going on.

October 31, 2022 Posted by | Science and Pseudo-Science | , , | 3 Comments

Biden’s Back-to-Back COVID Diagnoses Undermine Administration’s Narrative on His Health: NYT

Samizdat – 31.07.2022

Joe Biden tested positive for COVID-19 a second time on Saturday, just days after his announcement Wednesday that he had been given the all-clear following last week’s diagnosis.

The president’s COVID rebound case, while mild, will undermine the White House’s narrative on his health and “complicate his effort to turn his illness into a positive story,” The New York Times believes.

In its story on the president’s re-diagnosis, the liberal newspaper pointed out that the 79-year-old president, whom detractors have been attacking mercilessly over possible signs of dementia and a series of slips, falls, and flubs, has shown eagerness to display his physical prowess, “especially as he forecasts plans to run for a second term in 2024.”

Biden, the NYT recalled, showed himself working at the White House throughout his first quarantine after testing positive on July 21, and then sought to present Wednesday’s COVID all-clear as a “triumphal return to work in person.”

“Instead of the narrative of beating the virus, however, the president’s rebound case reinforces the unpleasant reality that the pandemic refuses to go away. Although the death toll has fallen dramatically, Covid-19 remains a fact of life for Americans, some of whom [mostly the vaccinated] have been infected multiple times,” the paper noted.

It added that the re-diagnosis would push back the president’s plans to travel the country to push his agenda and campaign in support of Democratic allies, who face a walloping at the upcoming November midterm elections, according to recent polling.

The NYT also questioned what impact Biden’s re-diagnosis might have on Pfizer – the pharma giant and advertising revenue moneybag that manufactures Paxlovid – the oral drug taken by Biden after his first COVID-19 diagnosis which has come under growing scrutiny for so-called “rebound” cases.

“Paxlovid rebound has become a source of debate within the scientific community and among Covid patients,” the newspaper carefully explained, admitting and that the real number of rebound cases is “likely significantly higher” than the low single digits referred to by Pfizer in its studies.

“Either way, experts stressed that Paxlovid has been notably successful in preventing more severe Covid-19 illnesses and hospitalizations,” the paper stressed, referencing the commonly used talking point in US media referring to both COVID treatments and vaccines. Previously, when studies revealed that the FDA-approved Pfizer, Moderna, and Johnson & Johnson jabs were subject to a “breakthrough infection” rate of 25 percent or more, particularly against Omicron variants, the pharmaceutical companies, government, and media shifted the goal posts, pointing instead to their [claimed] “protection against severe illness, hospitalization and death.”

In a video address following his re-diagnosis Saturday, President Biden, who had been double-vaxxed and double-boosted before getting COVID the first time, emphasized that he was “feeling fine,” that “everything is good,” and that he would be “working from home for the next couple days” with Commander, his German Shepherd.

July 31, 2022 Posted by | Science and Pseudo-Science | , , , , | 1 Comment

Biden Is Extending The Covid Emergency And Prolonging The War On Doctors

By Pierre Kory, MD | The Federalist | July 22, 2022

A recent New York Times/Siena College poll showing 64 percent of Democrats preferring a new standard-bearer in 2024 rocked the White House and the political landscape, but it should not have come as a big surprise. After all, President Joe Biden continues to fall short of the promises that drew many Democrats, including myself, to his candidacy in 2020: his pledge for a new strategy combatting Covid-19.

Consider the Food and Drug Administration’s recent decision allowing pharmacists to play doctor and prescribe Pfizer’s anti-viral treatment Paxlovid, which Biden himself, having contracted Covid-19, is now taking. The agency claims this is meant to increase access to the medicine, which must be taken as soon as symptoms arise. But the drug’s fact sheet is a tangled web of restrictions that will make it impractical for most pharmacies to take the risk. Why is the FDA encouraging this?

The answer is plain to anyone who has been following the plight of independent doctors during the pandemic. Our public health agencies — heavily influenced by the pharmaceutical industry and beholden to Biden’s “vaccine first” approach — are committed to diminishing the medical profession and centralizing authority with bureaucrats in Washington, D.C. They have prosecuted a relentless campaign to reduce physicians to cogs in a health care system that is aggressively transforming all medical professionals from providers to prescribers.

The problems with Paxlovid are no secret. FDA granted Pfizer emergency use authorization for the drug after a single trial with questionable results. The medicine has many contraindications, meaning it can’t be taken by someone who simultaneously would be taking certain anti-depressants, anti-seizure, anti-psychotic, cholesterol, or blood pressure medications. Furthermore, many Americans cannot take Paxlovid, given that nearly half of adults have cardiovascular disease.

The risks are plain to see in FDA’s guidance, which recommends referring the patient to a doctor if “sufficient information is not available to assess renal and hepatic function” or “potential drug interactions.” Numerous contraindications are listed, and caution is advised throughout. The burden is on the patient to furnish medical records to prove that he or she doesn’t have any significant kidney or liver disease, drug sensitivities, or other medications that could cause serious adverse events.

Nevertheless, pharmacies have spent months and millions of dollars lobbying for the right to play doctor and prescribe Paxlovid. The economic motives of such a move are clearly in their favor, as, unlike doctors, they profit directly from dispensing drugs. It’s no surprise the National Community Pharmacists Association celebrated the win as a “course correction.” Its CEO said, “Pharmacists are the drug therapy and drug interaction experts. This move opening up their ability to assess the need for and prescribe Paxlovid will improve patients’ timely access to treatments that will help keep them out of the hospital and alive.”

This may be as absurd a statement by a health organization as any I have heard in the pandemic. No pharmacist could ever safely dispense a novel medicine with an unprecedented amount of drug interactions without in-depth knowledge of the severity of the patient’s medical problems or the critical necessity of each of their other medicines. This fact was not lost on the American Medical Association, which temporarily snapped out of its woke-activist-induced coma to offer qualified criticism.

“While the majority of COVID-19 positive patients will benefit from Paxlovid, it is not for everyone, and prescribing it requires knowledge of a patient’s medical history, as well as clinical monitoring for side effects and follow-up care to determine whether a patient is improving—requirements far beyond a pharmacist’s scope and training,” American Medical Association President Jack Resneck Jr. said in a statement.

The tell is right there, though. The AMA is fine with Paxlovid as long as physicians are doing the prescribing. Ceding authority is the problem, which is why the agency previously called the idea “dangerous in practice and precedent” when the Biden administration first proposed it in the Test to Treat initiative.

Covid cases and deaths are down massively from their last peak in January. Most states have lifted restrictions and returned to normal. Yet just days after the FDA made this announcement, the Biden administration again extended the Covid public health emergency — because the president can’t lose the specter of Covid as a political tool.

Vaccination rates have leveled off, and Paxlovid sales bottomed out in April due to a combination of supply problems and sinking demand. Pfizer pushed expectations for the drug sky high, and now it needs to deliver on that promise. The FDA’s move shows how deftly the company has used the pandemic to influence government and public health agencies to serve its shareholders.

The pharmaceutical industry, led by Pfizer and in league with the Biden administration, is waging war against independent doctors who refuse to cede control over patient well-being — and they are winning. If there is any hope for change, it will come in November.

The red wave forming off our political shores is a culmination of many factors. Inflation and gas prices are hitting all-time highs, and just 13 percent of Americans believe the country is heading in the right direction. But relying on scare tactics to distract voters back to Biden is a strategy not supported by medical conditions on the ground.

Let’s hope whoever rides into Washington on that red wave will take on this fight with integrity.

Pierre Kory, MD, is president and chief medical officer of the Front-Line COVID-19 Critical Care Alliance.

July 23, 2022 Posted by | Corruption | , , | Leave a comment

Fauci Likely to Birth His Own COVID Variant After Paxlovid

By Dr. Joseph Mercola | July 13, 2022

Pfizer’s Paxlovid was granted emergency use authorization to treat mild to moderate COVID-19 in December 2021.1 The drug consists of nirmatrelvir tablets — the antiviral component — and ritonavir tablets, which are intended to slow the breakdown of nirmatrelvir.2

What started out as a slow rollout — only 40,000 or fewer prescriptions were written for the drug in the U.S. each week through April 2022 — has gained steam, with more than 160,000 Paxlovid prescriptions now being issued each week.3 As of June 30, 2022, 1.6 million courses of Paxlovid have been prescribed in the U.S. since its emergency use approval in December.4

Yet, this increase in prescribing could be contributing to one of the significant downfalls of the drug — the creation of selective pressure on SARS-CoV-2, which promotes mutations that could make it resistant to the drug.5 The U.S. Centers for Disease Control and Prevention also issued a warning to health care providers and public health departments about the potential for COVID-19 rebound after Paxlovid treatment.6

This recently happened to Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), who experienced a return of COVID-19 symptoms after taking Paxlovid. He then took a second course of the drug, which could trigger even more mutations in the virus.

Paxlovid Triggers Fauci’s COVID-19 Rebound

Fauci said he tested positive for COVID-19, with only minimal symptoms. As his symptoms increased, he took Paxlovid for five days, after which he tested negative for three consecutive days. On the fourth day of testing, he tested positive for COVID-19 again, with symptoms worse off than they were the first time.
“It was sort of what people are referring to as a Paxlovid rebound,” he said. “… Over the next day or so I started to feel really poorly, much worse than in the first go around.”7 He was then prescribed a second course of Paxlovid.

On June 30, he stated, “I went back on Paxlovid, and right now I am on my fourth day of a five-day course of my second course of Paxlovid. Fortunately, I feel reasonably good. I mean, I’m not completely without symptoms, but I certainly don’t feel acutely ill.”8 In the CDC’s health advisory regarding COVID-19 rebound after Paxlovid treatment it’s stated:9

“Recent case reports document that some patients with normal immune response who have completed a 5-day course of Paxlovid for laboratory-confirmed infection and have recovered can experience recurrent illness 2 to 8 days later, including patients who have been vaccinated and/or boosted …

These cases of COVID-19 rebound had negative test results after Paxlovid treatment and had subsequent positive viral antigen and/or reverse transcriptase polymerase chain reaction (RT-PCR) testing.”

COVID-19 Still Spreads During Paxlovid Rebound

People who take Paxlovid can still transmit COVID-19 to others, even if they’re asymptomatic, according to a preprint study.10 Study author Dr. Michael Charness of the Veterans Administration Medical Center in Boston told CNN, “People who experience rebound are at risk of transmitting to other people, even though they’re outside what people accept as the usual window for being able to transmit.”11

The CDC12 and Pfizer13 have suggested that sometimes COVID-19 naturally comes back after a person tests negative, implying that COVID-19 rebound is spontaneous and not necessarily linked to Paxlovid. However, Charness and colleagues didn’t find this to be the case. When they analyzed 1,000 cases of COVID-19 diagnosed among members of the National Basketball Association — none of whom took Paxlovid — no cases of COVID-19 rebound were found.14

Research published in Clinical Infectious Diseases 15 looked into why Paxlovid may be leading to rebound symptoms and suggests it could be the result of insufficient exposure to the drug.16 “Not enough of the drug was getting to infected cells to stop all viral replication,” UC San Diego Health reported. “They suggested this may be due to the drug being metabolized more quickly in some individuals or that the drug needs to be delivered over a longer treatment duration.”17

Pfizer Seeks FDA Approval for Paxlovid

Despite the many questions regarding Paxlovid’s association with rebound infections, Pfizer is moving ahead and seeking full approval of the drug from the FDA.18 The drug’s emergency use authorization restricts who the drug can be sold and marketed to. Once full FDA approval is granted, Pfizer can market the drug directly to consumers.

Paxlovid’s emergency use authorization allows it to be prescribed for adults and children ages 12 and older who are at high risk for progression to severe COVID-19.19 Pfizer estimates that up to 60% of the U.S. population meets these criteria and has at least one risk factor for severe illness, such as obesity or diabetes, making them eligible for the drug.20

However, concerns have risen over whether Paxlovid, which is said to cut the risk of hospitalization or death by 86% in high-risk patients, when taken within five days of symptoms starting,21 is effective in people who are not high-risk.

In fact, Pfizer stopped a large trial of Paxlovid in standard-risk patients because it didn’t show significant protection against hospitalization or death in this group.22 According to a news release from Pfizer:23

“In previously reported interim analyses, the company disclosed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met, and a non-significant 70% relative risk reduction was observed in the key secondary endpoint of hospitalization or death (treatment arm: 3/428; placebo: 10/426).

An updated analysis from 1,153 patients enrolled through December 2021 showed a non-significant 51% relative risk reduction (treatment arm: 5/576; placebo: 10/569). A sub-group analysis of 721 vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a non-significant 57% relative risk reduction in hospitalization or death (treatment arm: 3/361; placebo: 7/360).”

Is Paxlovid Triggering SARS-CoV-2 Mutations?

Initial reports have suggested that SARS-CoV-2 is not mutating and becoming resistant to Paxlovid, but some experts believe it’s only a matter of time before this occurs — and emerging research suggests it’s already happened.

David Ho, a virologist at the Aaron Diamond AIDS Research Center at Columbia University, was among the first to document resistance mutations in HIV 30 years ago and believes the same may be coming with SARS-CoV-2.24 He’s also experienced post-Paxlovid COVID-19 rebound firsthand. Bloomberg reported:25

“Ho said he came down with COVID on April 6 … His doctor prescribed Paxlovid, and within days of taking it, his symptoms dissipated and tests turned negative. But 10 days after first getting sick, the symptoms returned and his tests turned positive for another two days.

Ho said he sequenced his own virus and found that both infections were from the same strain, confirming that the virus had not mutated and become resistant to Paxlovid. A second family member who also got sick around the same time also had post-Paxlovid rebound in symptoms and virus, Ho says.

‘It surprised the heck out of me,’ he said. ‘Up until that point I had not heard of such cases elsewhere.’ While the reasons for the rebound are still unclear, Ho theorizes that it may occur when a small proportion of virus-infected cells may remain viable and resume pumping out viral progeny once treatment stops.”

Studies Show COVID-19 Virus Developing Paxlovid Resistance

Two separate studies cultured SARS-CoV-2 in a lab and exposed it to low levels of nirmatrelvir, which would kill some, but not all, of the virus. “Such tests are meant to simulate what might happen in an infected person who doesn’t take the whole regimen of the drug or an immunocompromised patient who has trouble clearing the virus,” Science reported.26

One of the studies revealed that SARS-CoV-2 developed three mutations after 12 rounds of nirmatrelvir treatment — “at positions 50, 166 and 167 in the string of amino acids that make up MPRO.”27 The mutations amounted to a 20-fold reduction in the virus’ susceptibility to nirmatrelvir.28 The other study29 also found mutations at positions 50 and 166, revealing that when they occurred together, SARS-CoV-2 became 80 times less susceptible to nirmatrelvir. According to the study:30

“Reverse genetic studies in a homologous infectious cell culture system revealed up to 80-fold resistance conferred by the combination of substitutions L50F and E166V. Resistant variants had high fitness increasing the likelihood of occurrence and spread of resistance.”

Lead study author Judith Margarete Gottwein with the University of Copenhagen told Science, “This tells us what mutations we should be looking for [in patients].”31 Ho, who was not involved in these studies, agreed that it appeared mutations were an inevitable outcome.

He told Science, “when you put pressure on the virus it escapes … Given the amount of infections out there, it’s going to come.”32 It’s also completely unknown what may happen when two courses of Paxlovid are taken in quick succession to treat COVID-19 rebound — as occurred with Fauci. It’s possible that ever-mutating COVID-19 variants could be created.

Other antivirals on the market to treat COVID-19 have also led to concerns over mutations. Molnupiravir (sold under the brand name Lagevrio) was developed by Merck and Ridgeback Therapeutics and approved by the FDA for emergency use December 23, 2021, for high-risk patients with mild to moderate COVID symptoms.

However, not only might it contribute to cancer and birth defects, it may also supercharge the rate at which the virus mutates inside the patient, resulting in newer and more resistant variants.33

Other Early COVID-19 Treatments Ignored

Using drugs that cause high rates of organ failure, like remdesivir, and drugs that cause the virus to rebound with a vengeance, like Paxlovid, and potentially trigger mutations don’t seem to be in the best interest of public health. The fact that U.S. health authorities have focused on these drugs to the exclusion of all others, including older drugs with high rates of effectiveness and superior safety profiles, sends a very disturbing message.

An investigation by Cornell University, posted on the University’s preprint server January 20, 2022, found ivermectin outperformed 10 other drugs against COVID-19, making it the most effective against the Omicron variant.34 It even outperformed Paxlovid, yet it’s been vilified by health officials and mainstream media.

Remdesivir costs between $2,340 and $3,120,35 and nirmatrelvir costs $529 per five-day treatment,36 while the average treatment cost for ivermectin is $58.37 Do you think this has anything to do with ivermectin’s vilification?

Paxlovid alone has cost U.S. taxpayers $5.29 billion,38 while safe and less expensive options exist. Dr. Pierre Kory, who is part of the group that formed the Front Line COVID-19 Critical Care Working Group (FLCCC) to advance early treatments for COVID-19, pleaded with the U.S. government early on in the pandemic to review the expansive data on ivermectin to prevent COVID-19, keep those with early symptoms from progressing and help critically ill patients recover — to no avail.39,40

However, if you’d like to learn more about its potential uses for SARS-CoV-2, FLCCC’s I-MASK+ protocol can be downloaded in full,41 giving you step-by-step instructions on how to prevent and treat the early symptoms of COVID-19.

Sources and References

July 14, 2022 Posted by | Corruption, Science and Pseudo-Science | , , | 2 Comments

Data Show FDA Process for Emergency Authorization of Pfizer, Merck COVID Pills Not Based on Science

By John Droz, Jr., M.S. | The Defender | March 7, 2022

The U.S. Food and Drug Administration (FDA) in December 2021 granted Emergency Use Authorization (EUA) to two COVID-19 early treatment oral drugs: Pfizer’s Paxlovid and Merck’s molnupiravir.

This was a major milestone, as until then, there were no FDA-endorsed pharmaceutical pill options for people diagnosed with COVID-19.

The standard medical therapy for a newly diagnosed person was: Go home, rest, drink water and go to the hospital if things get dire.

Now, after almost two years, people diagnosed with early stages of COVID-19 can be prescribed a pill!

As background, there are three stipulations a drug must meet in order to obtain EUA from the FDA:

  • There must be an emergency.
  • The treatment in consideration must be safe and offer 50% efficacy.
  • There must not be an alternative available treatment that is safe and effective.

Pfizer and Merck oversaw clinical trials that attempted to prove their products were safe and effective. In the letters of authorization issued to Pfizer and Merck, the FDA outlined what tests were done, what the results were, what some of the limitations and concerns are, etc.

The FDA then generated more detailed advisories to healthcare providers (doctors) for Paxlovid and molnupiravir. These documents give more specifics about use restrictions (e.g., not to children), potentially adverse effects of each drug (e.g., not to be used by pregnant women, etc.), potential conflicts with other drugs (quite a few), etc.

Here are four key points to consider regarding the Paxlovid and molnupiravir data:

  • The tests were conducted by the pharmaceutical companies themselves (not an unbiased entity).
  • No long-term testing was done on either of these drugs (the trials lasted a few months).
  • The effects on patients with many other diseases (e.g., Parkinson’s) were not evaluated and remain unknown.
  • The reported effectiveness of each drug (hospitalization or death: 88% and 30%) are relative not absolute. (See this explanation about this important point.)

OK, kudos to the FDA for giving consumers some early treatment options for dealing with COVID-19. It’s especially good that they are non-hospital, take-at-home therapies.

However, the question remains: How do these FDA-endorsed drugs compare to other over-the-counter (OTC) and non-patented drugs — especially ivermectin (IVM) and hydroxychloroquine (HCQ) — that are reported to have some early treatment effectiveness against COVID-19?

As a scientist (physicist) I try to be careful in analyzing data, to not only be accurate but to present it objectively and understandably.

In that light, see this table where I juxtapose Paxlovid and molnupiravir to IVM, HCQ and three OTC drugs: curcumin, Vitamin D and zinc. The comparisons made are based on about 20 COVID-19 factors (effectiveness, safety, cost, etc.).

Comparison of Major COVID-19 Early Treatment Oral Pharmaceuticals

Click here to increase the size of the chart and access the hyperlinks.

COVID chart

6 takeaways from comparison of Paxlovid and molnupiravir to IVM, HCQ, and OTCs

  • Pfizer’s Paxlovid is reported to have very high effectiveness.
  • HCQ and the curcumin have effectiveness comparable to Paxlovid.
  • Merck’s molnupiravir has very low effectiveness.
  • IVM, Vitamin D and Zinc have effectiveness far superior to molnupiravir.
  • Paxlovid and molnupiravir have more serious side effects than the others.
  • Paxlovid and molnupiravir cost considerably more than the non-patented options.

Are Pfizer and Merck oral treatment EUAs legal? 

Remember, federal law stipulates that an EUA can not be granted unless: “There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the disease or condition.”

The data in this analysis indicate there are “adequate and available alternatives for treating” COVID-19. If the data are accurate, then these EUAs have questionable legality.

Adequate and available alternatives for treating COVID-19 do, in fact, exist — the FDA has no scientific justification for ignoring IVM, HCQ, Vitamin D and zinc.

Further, if these FDA-issued EUAs for Paxlovid and molnupiravir violate federal statutes, a closer examination of the FDA’s COVID-19 vaccine EUAs seems warranted.

If the Pfizer and Merck EUAs are legal, then why haven’t HCQ and IVM also been given EUAs?

Considering the six takeaways listed above — plus the fact, as noted in the above table, that there have been successful HCQ and IVM studies much larger (~10x) than those done for Paxlovid and molnupiravir — exactly why has the FDA not issued EUAs for IVM and HCQ?

The comparative in Table 1 adequately demonstrates there is no justification for the FDA’s refusal to grant EUAs to IVM and HCQ.

If the FDA had granted EUAs for HCQ and IVM a year ago, hundreds of thousands of COVID-19 deaths would have been prevented.

What FDA policy, procedure or precedent took priority over preventing hundreds of thousands of American deaths?

What about monoclonal antibody therapies?

Let us now expand our comparisons to include current monoclonal antibody therapies:

Comparison of Major COVID-19 Early Treatment Pharmaceuticals

Click here to increase the size of the chart and access the hyperlinks.

Early treatment chart

Note that the four key points identified above, regarding the Paxlovid and molnupiravir data, all apply here.

Some of the main takeaways from this comparison are:

  • Sotrovimab has the highest effectiveness — but the least amount of data.
  • HCQ and curcumin have effectiveness comparable to the bamlanivimab+ and casirivimab+ combinations.
  • The first FDA EUA given to bamlanivimab turned out to be a mistake (as health issues were discovered).
  • All the monoclonals have more serious side effects than the non-EUA options.
  • All the monoclonals cost considerably more than the non-EUA options.
  • All the monoclonals have much less safety data than the non-EUA options.

Again, this comparison shows that IVM, HCQ, curcumin, vitamin D and zinc compare very favorably to all of the early treatments that received EUA from the FDA.

John Droz, Jr. is an independent North Carolina physicist.

© 2022 Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.

March 8, 2022 Posted by | Corruption, Deception, Science and Pseudo-Science, Timeless or most popular | , , , , , , | Leave a comment

If you are a vaccine company executive, it’s time to slam the brakes

Pfizer’s CEO Albert Bourla sees the dangers ahead, as his very carefully worded interview (worthy of close review) with CNBC yesterday shows.

By Alex Berenson | Unreported Truths | January 11, 2022

Remember NINJA loans?

NINJA stood for “No income, no job/assets.” Back in the mid-aughts, when the banks and not the regulators were the ones going crazy and setting the financial system on fire with free money, they were all the rage.

I remember hearing ads for them in 2006 and 2007 and thinking, this has to be a bait and switch. You cannot walk into Your Friendly MegaBank and walk out with a few hundred grand for a house with no proof you even have a job! A job seems pretty basic.

But you could. And people did. Lots of people.

Underlying this madness was a model, naturally. American housing prices had never collapsed nationally and simultaneously since at least the Depression. Therefore the models that the banks and mortgage originators used said they never would.

Therefore on a national basis the collateral – the houses – underlying the mortgages would always be fine, even if the borrowers couldn’t repay them. The lenders just needed to be in different markets to be geographically protected. Besides, the bankers were all reselling the loans and offloading the risk. They got paid up front, whether the loans were paid back or not.

It was a very good business.

Until it went bad.

“How did you go bankrupt?” Bill asked.

“Two ways,” Mike said. “Gradually, then suddenly.”

You remember 2008. You were there.

In a matter of months, the big banks became the most hated institutions in the United States. The desperation to blame them ran so deep that we all seemed to agree collectively that the borrowers were the victims. The people who had taken the money had no responsibility for signing those loans, much less repaying them.

Obviously, that formulation was simplistic. Many of the NINJA and similar borrowers no doubt understood the game they were playing. They were hoping to buy and flip houses they couldn’t afford.

No matter. They had lost. Anyway, we couldn’t make villains out of millions of ordinary people. So we understandably focused our anger on the Wall Street tycoons who had crashed our financial system and made hundreds of billions of dollars.

Fast-forward to 2022.

This time around the myth of the truly innocent victim is not a myth.

The hundreds of millions of people who have received shots of mRNA/LNP and DNA/AAV Covid vaccines had no real idea what they were taking.

They did so on the urging of the vaccine companies and health authorities, who told them that in doing so they would protect themselves and their families and end the Covid epidemic. The statements were public. Many are less than a year old. They cannot be suppressed or memory-holed, no matter how hard anyone wants to try.

Every single one of those statements has proven wrong – so wrong that the companies, which are at much greater legal risk than the public health authorities – no longer even try to defend them.

Here’s what Albert Bourla, Pfizer’s chief executive officer, said on Monday in an interview on CNBC:

The hope is that we will achieve something that will have way, way better protection, particularly against infections because the protection against the hospitalizations and the severe disease, it is, it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose.

Read those words very carefully.

Protection against “severe disease” is “reasonable right now” for people who have taken a “third dose” of Pfizer’s vaccine.

Put aside the fact that even those words are at best an optimistic interpretation of current data.

Put aside the fact that Pfizer has NEVER compared a three-dose vaccine regimen to a placebo in a clinical trial.

Put aside the fact that “reasonable right now” suggests that any effect of a third dose will not last.


Even against “the hospitalizations and the severe disease.”

You need to be “having let’s say the third dose” for protection against those.

I didn’t say it.

Pfizer’s CEO did. (And I can’t wait to see Twitter’s lawyers try to explain it when they defend my fifth strike. It goes WAY further than that tweet did.)

Ask yourself why Pfizer’s chief executive officer would be MORE negative about his company’s vaccine and future boosters than the public health authorities and the media bluechecks.

Here’s a hint: not because Pfizer has a history of honest and ethical behavior to uphold.

Most people don’t understand yet how badly they were conned.

But they will.

The raw numbers are stark – in Ontario, for example, 76 percent of hospitalized people and 56 percent of those in intensive care are now vaccinated. Both the raw numbers and the percentages have soared in the last two weeks.

The data out of Europe are similar. The only reason the American data look different is that we don’t get to see the raw numbers. Instead, health authorities provide meaningless adjusted rate ratios (adjusted for age of vaccinated people, but NOT for healthy vaccine user bias – the fact that frailest elderly people are often not vaccinated because they cannot be.) Further, American hospitals report people as unvaccinated when their vaccine status is “unknown,” further skewing the ratios.

But you can trust Albert Bourla: vaccine protection against severe outcomes drops over time – and drops much more quickly against the Omicron variant.

That’s one side of the coin.

The flip side is adverse events. We don’t know how bad those are after a third dose, much less a fourth or fifth or more. (How can we? Remember, the companies didn’t test three doses against placebo.)

But the third-shot myocarditis data looks bad. It suggests a dose-dependent response. And the rise in all-cause deaths across Europe in the last few months cannot be ignored, even if the health authorities are ignoring it.

I suspect the smartest people at the companies are increasingly aware of the potential crisis of repeated dosing. Which may be why Bourla also said in the CNBC interview, “I don’t know if there is a need for a fourth booster.”

What? In the same interview where Pfizer’s CEO warned people not to expect long-lasting protection from a third shot – “reasonable right now” – he also pivoted away from more boosters?

Instead Bourla talked up Paxlovid, his company’s new $530 per treatment antiviral. “This is where most of the effort of most of the governments is moving.”

Actually Paxlovid is basically unavailable right now; Pfizer has promised 120 million doses worldwide in 2022, but as of 10 days ago, only 180,000 were available.

So what’s Bourla’s game? Doesn’t he want to sell as many vaccines as he can?

Maybe not. Especially not with a drug that potentially can be huge ($530 x 120 million = $62 billion, give or take, and Pfizer won’t have to share it with BioNTech).

More important for Bourla, the real risk to Pfizer – and to him – comes from side effects. People will be angry when they figure out that they’ve been conned into taking vaccines that didn’t work. But most of them won’t be furious, especially since Omicron appears much milder than earlier variants. Zero efficacy probably won’t destroy Pfizer or get anyone indicted.

But side effects might. People will be FURIOUS if they think they have been conned into taking vaccines that didn’t work and potentially hurt them, or their parents, or their kids.

Right now the rate of reported serious vaccine injury is just low enough that the companies and vaccine fanatics can argue it’s not real, it’s a statistical artifact, the VAERS reports are fake (they’re not), etc. The third dose appears to be changing that equation somewhat.

Who knows what future doses will bring? Nobody, including Albert Bourla, though his scientists may have shot up enough mice and monkeys to give him a better idea than the rest of us.

Unlike BioNTech and Moderna, Pfizer isn’t stuck with mRNA. It is a $300 billion pharmaceutical company that is busily taking its vaccine loot to buy lots of research. Plus it now has Paxlovid.

(Big investors have figured all this out, by the way. The stocks of BioNTech and Moderna are down more than 50 percent since the peak of the vaccine frenzy in August, while Pfizer’s is up 20 percent and near an all-time high. Like Big Pharma, Wall Street is a lot of things, but it ain’t dumb.)

So the prudent move for Albert Bourla, Doctor of Veterinary Medicine, PhD., is to begin to tamp expectations for vaccines, slow-walk more boosters, and hope that Omicron does his job for him. His biggest problem is probably that the public health authorities are a lot stupider than he is and continue to push boosters.

I’d love to know what Pfizer is telling them privately. I’m gonna guess it’s not in email, though.

January 11, 2022 Posted by | Deception, Science and Pseudo-Science, Timeless or most popular, War Crimes | | Leave a comment

Paxlovid: What we should know about Pfizer’s new COVID treatment medicine

By Joel S Hirschhorn | December 24, 2021

The pro-drug industry mainstream media are insanely positive over the newly FDA approved Pfizer antiviral COVID treatment pills.

The drug, Paxlovid, received an emergency use authorization by FDA for use in patients 12 years old and up who have tested positive for COVID-19 and are at high risk.

Now is the time to speak calmly and accurately about Paxlovid. First, everyone should appreciate that there was very little testing of the short- and long-term safety of this product, exactly what happened with COVID vaccines. Really good testing of a new drug should take many months or even years.

All you get is positive news for this new drug – actually a combination of drugs.

Here are brief summary statements about this new product:

It was approved by the FDA without any external meetings, serious reviews of test data or opportunity for public input. Pretty much all the regulatory work was done behind closed doors. Terrific for Pfizer. Bad for the public.

Of importance, note that in the trials only 21% of people had a comorbidity, while in reality 94% of COVID deaths have at least one comorbidity, and the average number of underlying medical conditions is four.

As to antiviral science, protease enzymes must be present for the virus to successfully infect by completing the cycle before taking the cell over. Paxlovid or any drug classified as a ‘Protease Inhibitor’ will inhibit or decrease the protease enzyme interfering with the virus.  Paxlovid blocks the 3CLPro protease from chopping up the long protein into pieces.  The virus can’t separate out which pieces to cut out and assemble. It can’t make copies of itself. The covid infection quickly stops

Contrary to what the government says, ivermectin is the most successful and proven protease inhibitor in use worldwide. Just as with Paxlovid, ivermectin decreases the protease enzyme but… there are benefits of ivermectin in covid treatment that are not present in Paxlovid. Additional actions of ivermectin include anti-coagulant action and anti-inflammatory actions, both observed in covid infections. And IVM has been safely used for decades and there have been many medical studies as well as clinical results showing its antiviral and anti-inflammatory effectiveness.

Paxlovid requires combination with an HIV/AIDS drug, Ritonavir, preventing the breakdown of the Paxlovid so it may inhibit or decrease the enzyme interrupting the viral life cycle. Ritonavir acts as a booster for Paxlovid, keeping it active inside a person’s body.  Ritonavir also has its own black box warning and side effects include life-threatening liver, pancreas and heart issues.  Does the public really want to take an HIV/AIDS drug?

A course of the treatment is 20 Paxlovid pills and 10 ritonavir pills taken over five days. Taking 6 pills daily can pose challenges for many elderly people in particular.

According to Pfizer’s press release, for people with proven COVID infection, Paxlovid reduces hospitalization/death by 89% when taken within three days of symptom onset. So in the treatment group there was 5 of 697 hospitalized with no deaths compared to 44/682 hospitalized with 9 subsequent deaths.

Also reported was an approximate 10-fold decrease in viral load at day 5, relative to placebo, indicating robust activity against SARS-CoV-2 and representing (supposedly) the strongest viral load reduction reported to date for a COVID-19 oral antiviral agent.

How interesting it would have been to test the Pfizer drug against an ivermectin protocol.

For example, how does the Pfizer drug compare with the Dr. George Fareed and Dr. Brian Tyson protocol? Well, Fareed and Tyson had many more patients (about 7,000) taking the drug combo and yet they had fewer hospitalizations (4) and the same number of deaths (0).  So, you’re way better off with the Fareed and Tyson protocol. And the safety protocol of IVM after billions of uses globally is far better proven than for the Pfizer product.

For a good discussion on how IVM compares to Paxlovid see this article.  Especially on scientific evidence of ivermectin’s ability to block 3CL protease.

In terms of safety, the most common side effects reported during treatment and up to 34 days after the last dose of Paxlovid were dysgeusia (taste disturbance), diarrhea and vomiting. But what more serious side effects may turn up months or years later?

Paxlovid must not be used with certain other medicines [but it has not been said exactly which ones], either because due to its action it may lead to harmful increases in their blood levels, or because conversely some medicines [which ones?] may reduce the activity of Paxlovid itself. The list of medicines that must not be used with Paxlovid is included in the proposed conditions for use [not yet fully disclosed].  Paxlovid must also not be used in patients with severely reduced kidney or liver function.

Paxlovid is not recommended during pregnancy and in people who can become pregnant and who are not using contraception. Breastfeeding should be interrupted during treatment. These recommendations are because laboratory studies in animals suggest that high doses of Paxlovid may impact the growth of the fetus.

As to availability, Pfizer CEO Bourla recently said the company can manufacture 80 million courses in 2022, with 30 million available in the first half of the year. That is not enough to serve many millions of Americans coming down with symptoms and a positive test result.

This too was said, tens of thousands of the pills will ship in the US before the end of 2021 and hundreds of thousands more are expected at the beginning of 2022, a Pfizer spokesperson told the Wall Street Journal.  The US government is paying Pfizer $5.3 billion for 10 million treatment courses that will be delivered by the end of next year, according to the paper. Will medical insurance cover $530 per course?

Always follow the money. A month ago, SVB Leerink analyst Geoffrey Porges projected the drug will generate $24.2 billion in 2022 sales. Together with the company’s megablockbuster COVID-19 vaccine, Pfizer could be looking at $50 billion in peak pandemic vaccine and drug sales, Cantor Fitzgerald analyst Louise Chen wrote earlier this month.  No surprise that some top Pfizer executives have become billionaires.

December 25, 2021 Posted by | Corruption | , , , | 1 Comment